An HIV-COVID-19 co-infection dynamics is modeled mathematically assimilating the vaccination mechanism that incorporates endogenous modification of human practices generated by the COVID-19 prevalence, absorbing the relevance of the treatment mechanism in suppressing the co-infection burden. Envisaging a COVID-19 situation, the HIV-subsystem is analyzed by introducing COVID-19 vaccination for the HIV-infected population as a prevention, and the "vaccination influenced basic reproduction number" of HIV is derived. The mono-infection systems experience forward bifurcation that evidences the persistence of diseases above unit epidemic thresholds. Delicate simulation methodologies are employed to explore the impacts of baseline vaccination, prevalence-dependent spontaneous behavioral change that induces supplementary vaccination, and medication on the dual epidemic. Captivatingly, a paradox is revealed showing that people start to get vaccinated at an additional rate with the increased COVID-19 prevalence, which ultimately diminishes the dual epidemic load. It suggests increasing the baseline vaccination rate and the potency of propagated awareness. Co-infection treatment needs to be emphasized parallelly with single infection medication under dual epidemic situations. Further, an optimization technique is introduced to the co-infection model integrating vaccination and treatment control mechanisms, which approves the strategy combining vaccination with awareness and medication as the ideal one for epidemic and economic gain. Conclusively, it is manifested that waiting frivolously for any anticipated outbreak, depending on autogenous behavior modification generated by the increased COVID-19 prevalence, instead of elevating vaccination campaigns and the efficacy of awareness beforehand, may cause devastation to the population under future co-epidemic conditions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1063/5.0186156 | DOI Listing |
JAMA Cardiol
January 2025
Ifakara Health Institute, Ifakara Branch, Ifakara, United Republic of Tanzania.
Importance: Hypertension is the primary cardiovascular risk factor in Africa. Recently revised World Health Organization guidelines recommend starting antihypertensive dual therapy; clinical efficacy and tolerability of low-dose triple combination remain unclear.
Objectives: To compare the effect of 3 treatment strategies on blood pressure control among persons with untreated hypertension in Africa.
BMC Cancer
January 2025
Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Background: Neuroblastoma, a prevalent extracranial solid tumor in pediatric patients, demonstrates significant clinical heterogeneity, ranging from spontaneous regression to aggressive metastatic disease. Despite advances in treatment, high-risk neuroblastoma remains associated with poor survival. SLC1A5, a key glutamine transporter, plays a dual role in promoting tumor growth and immune modulation.
View Article and Find Full Text PDFBMC Public Health
January 2025
Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.
Background: Long-lasting insecticidal nets (LLINs) were once fully effective for the prevention of malaria; however, mosquitoes have developed resistance to pyrethroids, the main class of insecticides used on nets. Dual active ingredient LLINs (dual-AI LLINs) have been rolled out as an alternative to pyrethroid (PY)-only LLINs to counteract this. Understanding the minimum community usage at which these LLINs elicit an effect that also benefits non-users against malaria infection is important.
View Article and Find Full Text PDFArch Osteoporos
January 2025
Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Unlabelled: Rural communities face healthcare challenges. This study assessed a multicomponent intervention to improve hospital visits and anti-osteoporosis medication (AOM) treatment rates. A total of 567 patients were randomized into three groups.
View Article and Find Full Text PDFSci Rep
January 2025
Infectious Diseases Clinic, Azienda Sanitaria Universitaria Friuli Centrale, 33100, Udine, Italy.
Enterococcus faecalis is responsible for numerous serious infections, and treatment options often include ampicillin combined with an aminoglycoside or dual beta-lactam therapy with ampicillin and a third-generation cephalosporin. The mechanism of dual beta-lactam therapy relies on the saturation of penicillin-binding proteins (PBPs). Ceftobiprole exhibits high affinity binding to nearly all E.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!